Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | ||
Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete |